The First Step is a CONFIRMED GENETIC DIAGNOSIS
Confirming mutations in both copies of the RPE65 gene is the first step to determine if a patient may be appropriate for treatment with LUXTURNA. Your healthcare professional will also determine if you have enough remaining cells in your retina.
Spark® Therapeutics is committed to providing access to an accurate genetic diagnosis and is offering a free* RPE65 genetic test, which can be ordered by your healthcare professional. Please read below to find out more about eligibility for this test. Steps for each patient will differ depending on where you are in your treatment journey.
If you have not yet been genetically tested for mutations in both copies of the RPE65 gene, our simple screener may help determine if you should ask your healthcare professional about a free* RPE65 genetic test available from Spark Therapeutics.
If you have confirmed mutations in both copies of the RPE65 gene, Spark Generation Patient ServicesSM can provide the following support services†:
A caring support team from confirmed diagnosis through post-treatment follow-up
A single point of contact to help you navigate insurance coverage and connect you with financial assistance resources as needed
Help coordinating your visits to the treatment center
Answers for any nonmedical questions you may have along the way
Contact Spark Therapeutics Generation Patient Services℠ to enroll.Visit Patient Services
*Participation in the test is subject to the Terms and Conditions.
†Participation in Spark Therapeutics Generation Patient ServicesSM is voluntary. You may choose to participate in all, some, or none of the services offered. Participating or deciding not to participate in these services will have no effect on your ability to get treatment or the nature of your treatment or care. Generation Patient Services does not provide medical advice. You should always rely on the direction of your healthcare professional for treatment and care.